Ignite Creation Date:
2025-12-24 @ 10:40 PM
Ignite Modification Date:
2026-02-08 @ 1:12 AM
Study NCT ID:
NCT01706835
Status:
COMPLETED
Last Update Posted:
2022-02-10
First Post:
2012-10-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
Sponsor:
ImmunityBio, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
ALDOXORUBICIN-P1-PK-01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None